GlycoErase™ B3GALT5 Knockout Glycoengineered Cell (CAT#: GLJF-0825-JF132)

Description	GlycoErase™ B3GALT5 knockout glycoengineered cell removes β-1,3-galactosyltransferase 5, an enzyme implicated in type 1 Lewis antigen synthesis, elevated in gastrointestinal and pancreatic cancers. This model supports cancer glycomics and biomarker research.
Product Type	KO Cell Lines
Cell Line	As requested by the client.

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	B3GALT5
Full Name	Beta-1,3-Galactosyltransferase 5
Alternative Name	B3T5; B3GalT-V; beta3Gal-T5; GLCT5
Location	21q22.2
Gene ID	10317
Summary	May be involved in the synthesis of type 1 Lewis antigens, which are often elevated in gastrointestinal and pancreatic cancers.